Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 16 October 2007
Vol. 2007, Issue 408, p. tw377
[DOI: 10.1126/stke.4082007tw377]


Medicine Slowing Tumor Growth with a One-Two Punch

Paula A. Kiberstis

Science, AAAS, Washington, DC 20005, USA

Drugs that inhibit receptor tyrosine kinases (RTKs) have emerged as promising anti-cancer therapies in clinical trials, but certain solid tumors such as glioblastoma multiforme (GBM) respond poorly to them. Work by Stommel et al. may help explain why GBM, an aggressive form of brain cancer, is so refractory to this class of drugs, which are typically administered as single agents. Glioblastoma cells display concomitant activation of multiple RTKs, all of which stimulate the phosphatidylinositol 3-kinase (PI3K) signaling pathway, a critical driver of cell growth. In preclinical models, combinations of agents targeting multiple RTKs were more powerful than single agents in inhibiting the PI3K pathway and slowing tumor cell growth. These results suggest a potential strategy for optimizing the efficacy of RTK inhibitors in GBM, an idea that can now be tested in clinical trials.

J. M. Stommel, A. C. Kimmelman, H. Ying, R. Nabioullin, A. H. Ponugoti, R. Wiedemeyer, A. H. Stegh, J. E. Bradner, K. L. Ligon, C. Brennan, L. Chin, R. A. DePinho, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007). [Abstract] [Full Text]

Citation: P. A. Kiberstis, Slowing Tumor Growth with a One-Two Punch. Sci. STKE 2007, tw377 (2007).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882